Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 121

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 121
---
, such as DOR agonists, and an immune effector, such as a T cell modulator, compositions comprising the same and methods of treating a disease, such as cancer, by administering the molecular conjugates. Earliest Expected Expiration Date: 6/26/2035

| Country |     | App. No.  |     | Filing Date |     | Grant Date |     | Patent No. |     | Status   |
| US      |     | 15/321316 |     | 12/22/2016  |     | 10/22/2019 |     |   10449227 |     | Granted  |
| US      |     | 16/659207 |     | 10/21/2019  |     |            |     |            |     | Inactive |
| US      |     | 17/889456 |     | 8/17/2022   |     |            |     |            |     | Inactive |
| US      |     | 18/130049 |     | 4/3/2023    |     |            |     |            |     | Pending  |

77

PCT/US2021/022464 (filed 3/16/2021) – “Delta opioid receptor antagonists reprogram immunosuppressive microenvironment to boost immunotherapy” Applicants: H. Lee Moffitt Cancer Center Summary: Relates to (a) methods of stimulating endogenous T cells, increasing the efficacy of adoptive immunotherapy, or reprogramming immunosuppressive tumor microenvironments, immunosuppressive myelopoiesis, or myeloid-derived suppressor cells by administering a DOR antagonist; (b) combination immunotherapies comprising an adoptive immunotherapy or an immune system activator and a DOR antagonist and methods of using the same to treat cancer; (c) methods of treating autoimmune disease or microbial infection by administering a DOR agonist, optionally with an immunosuppressor; and (d) combination therapies comprising a DOR agonist and an immunosuppressor. Earliest Expected Expiration Date: 3/16/2041

| Country |     | App. No.  |     | Filing Date |     | Grant Date |     | Patent No. |     | Status  |
| US      |     | 17/912300 |     | 9/16/2022   |     |